STAT3 and breast carcinoma: In cancer, a leading approach has been to induce antagonist/dominant negative variants of oncogenic proteins (reviewed in [55]), for example, in the case of signal transducer and activator of transcription 3 (STAT3), where redirection of its splicing to the antitumorigenic Stat3 beta variant leads to full tumor regression in breast cancer mouse models [65].